The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Primary results of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S-1 (CS) and docetaxel/cisplatin/S-1 (DCS) as neoadjuvant chemotherapy for locally advanced gastric cancer.
 
Takaki Yoshikawa
Honoraria - Abbott Nutrition; Ajinomoto; Chugai Pharma; Daiichi Sankyo; Johnson & Johnson; Lilly; Medtronic; Nihonkayaku; Olympus; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Consulting or Advisory Role - Chugai Pharma; MSD Oncology; Novartis
Research Funding - Chugai Pharma; Novartis; Taiho Pharmaceutical; Yakult Pharmaceutical
 
Kentaro Sakamaki
Honoraria - Ono Pharmaceutical; Taiho Pharmaceutical
 
Kazuhiro Nishikawa
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; Taiho Pharmaceutical
Research Funding - Ono Pharmaceutical; Taiho Pharmaceutical
 
Kazumasa Fujitani
No Relationships to Disclose
 
Kazuaki Tanabe
No Relationships to Disclose
 
Yuichi Ito
No Relationships to Disclose
 
Takanori Matsui
No Relationships to Disclose
 
Akira Miki
No Relationships to Disclose
 
Hiroshi Nemoto
No Relationships to Disclose
 
Tetsu Fukunaga
No Relationships to Disclose
 
Yutaka Kimura
No Relationships to Disclose
 
Naoki Hirabayashi
No Relationships to Disclose
 
Tsutomu Hayashi
Honoraria - Ono Pharmaceutical